Company research
ARS Pharmaceuticals, Inc.
CIK 1671858Updated Sep 26, 2026
SecuritySPRY · NASDAQ · equity
Name history
Silverback Therapeutics, Inc. · through Nov 8, 2022
SPRY price & chart
Loading TradingView…
NASDAQ:SPRY on TradingView ↗About the company
ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy® (trade name EURneffy® in the EU and UK), an epinephrine nasal spray indicated in the United States for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children aged 4 years and older who weigh 15 kg or greater. For more information, visit www.ars-pharma.com and follow us on LinkedIn and X.
In the news
Kaplan Fox Alerts ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors Who Suffered Losses to a Securities Class Action – Deadline is October 5, 2026 ↗
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRY ↗
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRY ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 327,652,000Source | 351,153,000Source | 233,188,000Source | 281,435,000Source |
| Property, Plant and Equipment, NetUSD | 2,465,000Source | 1,029,000Source | 574,000Source | 329,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 14,452,000Source | 7,371,000Source | — | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 41,317,000Source | 50,817,000Source | 70,971,000Source | 210,518,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 25,347,000Source | 8,175,000Source | — | — |
| Inventory, NetUSD | 31,422,000Source | 5,212,000Source | — | — |
| Assets, CurrentUSD | 284,896,000Source | 334,295,000Source | 231,726,000Source | 277,700,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 6,194,000Source | 6,886,000Source | 3,366,000Source | 3,319,000Source |
| Operating Lease, Right-of-Use AssetUSD | — | 37,000Source | 250,000Source | 445,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 213,394,000Source | 94,355,000Source | 2,428,000Source | 8,549,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 10,000Source | 10,000Source | 10,000Source | 9,000Source |
| Additional Paid in CapitalUSD | 408,726,000Source | 379,873,000Source | 362,004,000Source | 349,408,000Source |
| Retained Earnings (Accumulated Deficit)USD | -294,603,000Source | -123,305,000Source | -131,303,000Source | -76,938,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 125,000Source | 220,000Source | 49,000Source | 407,000Source |
| Stockholders' Equity Attributable to ParentUSD | 114,258,000Source | 256,798,000Source | 230,760,000Source | 272,886,000Source |
| Liabilities and EquityUSD | 327,652,000Source | 351,153,000Source | 233,188,000Source | 281,435,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 39,145,000Source | 23,440,000Source | 2,391,000Source | 5,444,000Source |
| Operating Lease, Liability, CurrentUSD | — | 42,000Source | 237,000Source | 230,000Source |
| Accounts Payable, CurrentUSD | 5,725,000Source | 9,870,000Source | 759,000Source | 1,659,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | 0Source | 37,000Source | 251,000Source |
| Additional Financial Items | ||||
| Deferred Tax Liabilities, NetUSD | 394,000Source | 138,000Source | 112,000Source | 249,000Source |
| Long-term DebtUSD | 96,374,000Source | — | — | — |
| Short-term InvestmentsUSD | 203,669,000Source | 263,205,000Source | 157,389,000Source | 63,863,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 22,095,000Source | 14,534,000Source | 9,235,000Source | 5,843,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 17,205,000Source | 8,175,000Source | — | — |
| Increase (Decrease) in InventoriesUSD | 21,986,000Source | 5,945,000Source | — | — |
| Deferred Income Tax Expense (Benefit)USD | 0Source | 0Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -170,866,000Source | 13,548,000Source | -59,266,000Source | -40,078,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 56,768,000Source | -106,101,000Source | -87,180,000Source | -199,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 339,000Source | 563,000Source | 175,000Source | 199,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 104,598,000Source | 72,399,000Source | 6,899,000Source | 190,732,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -9,500,000Source | -20,154,000Source | -139,547,000Source | 150,455,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 41,317,000Source | 50,817,000Source | 70,971,000Source | 210,518,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 2,452,000Source | — | — | — |
| Income Taxes Paid, NetUSD | 200,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | — | 14,534,000Source | 9,235,000Source | 5,843,000Source |
| Amortization of Intangible AssetsUSD | 800,000Source | 100,000Source | — | — |
| DepreciationUSD | — | 79,000Source | 73,000Source | — |
| Depreciation, Amortization and Accretion, NetUSD | — | — | — | 319,000Source |
| Gain (Loss) on InvestmentsUSD | — | — | 0Source | -140,000Source |
| General and Administrative ExpenseUSD | — | — | 47,284,000Source | 18,456,000Source |
| Income Tax Expense (Benefit)USD | -80,000Source | 288,000Source | 0Source | 0Source |
| Inventory Write-downUSD | 2,160,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -171,298,000Source | 7,998,000Source | -54,365,000Source | -34,682,000Source |
| Nonoperating Income (Expense)USD | — | — | — | 834,000Source |
| Operating Costs and ExpensesUSD | — | 2,066,000Source | 1,796,000Source | — |
| Operating ExpensesUSD | 263,726,000Source | 92,232,000Source | 67,550,000Source | 36,832,000Source |
| Other Nonoperating Income (Expense)USD | 8,070,000Source | 11,369,000Source | 13,155,000Source | 974,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 84,278,000Source | 89,149,000Source | 30,000Source | 1,316,000Source |
| Selling, General and Administrative ExpenseUSD | 230,122,000Source | 71,675,000Source | 940,000Source | — |
| Operating Income (Loss)USD | -179,448,000Source | -3,083,000Source | -67,520,000Source | -35,516,000Source |
| Other Nonoperating Income (Expense)USD | 8,070,000Source | 11,369,000Source | 13,155,000Source | 974,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -171,378,000Source | 8,286,000Source | — | — |
| Income Tax Expense (Benefit)USD | -80,000Source | 288,000Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -171,298,000Source | 7,998,000Source | -54,365,000Source | -34,682,000Source |
| Earnings Per Share, BasicUSD per share | -1.74Source | 0.08Source | -0.57Source | -0.87Source |
| Earnings Per Share, DilutedUSD per share | -1.74Source | 0.08Source | -0.57Source | -0.87Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 98,566,481Source | 96,936,661Source | 95,215,322Source | 39,956,043Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 98,566,481Source | 102,390,828Source | 95,215,322Source | 39,956,043Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 800,000Source | 100,000Source | — | — |
| Current Income Tax Expense (Benefit)USD | -80,000Source | 288,000Source | — | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | 1,367,000Source | 100,000Source | 100,000Source | — |
| Gain (Loss) on InvestmentsUSD | — | — | 0Source | -140,000Source |
| General and Administrative ExpenseUSD | — | — | 47,284,000Source | 18,456,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -171,372,000Source | — | — | — |
| Nonoperating Income (Expense)USD | — | — | — | 834,000Source |
| Operating Costs and ExpensesUSD | — | 2,066,000Source | 1,796,000Source | — |
| Operating ExpensesUSD | 263,726,000Source | 92,232,000Source | 67,550,000Source | 36,832,000Source |
| Research and Development ExpenseUSD | 13,181,000Source | 19,580,000Source | 20,266,000Source | 18,376,000Source |
Filing attachments
spry-ex99_1.htm · 8-K · 2026-08-13
EX-99.1 2 spry-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results $26.2 million in U.S. neffy® net product revenue in Q2 2026; total U.S. epinephrine market share for Type 1 allergies of 5% and 8% share within field-targeted accounts Commercial investment realigned toward targeted provider engagement, significantly reducing total operating expenses for 2H 202…
Read attachment ↗spry-ex99_1.htm · 8-K · 2026-05-15
EX-99.1 2 spry-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update Q1 2026 total revenue of $22.7 million including neffy U.S. net product revenue of $17.5 million CVS Caremark proposal in final stages of approval process; definitive update anticipated in early June Sales force expansion to 148 representatives completed Phase 2b CSU study interim population fully enrolled, and on track for Q4 2026 readout Confer…
Read attachment ↗spry-ex99_2.htm · 8-K · 2026-05-15
EX-99.2 3 spry-ex99_2.htm EX-99.2 May 2026 Corporate Presentation neffy - the transformative needle-free solution for severe allergic reactions Exhibit 99.2 NASDAQ: SPRY Forward-looking statements Statements in this presentation that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this presentation include, without limitation, statements regarding: the potential ma…
Read attachment ↗spry-ex99_1.htm · 8-K · 2026-03-09
EX-99.1 2 spry-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization neffy delivers $72.2 million of U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million in cash, cash equivalents and short-term investments supports operating plan through anticipa…
Read attachment ↗spry-ex99_2.htm · 8-K · 2026-03-09
EX-99.2 3 spry-ex99_2.htm EX-99.2 March 2026 Corporate Presentation neffy - the transformative needle-free solution for severe allergic reactions Exhibit 99.2 NASDAQ: SPRY Forward-looking statements Statements in this presentation that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this presentation include, without limitation, statements regarding: the potential …
Read attachment ↗spry-ex99_1.htm · 8-K · 2025-11-10
EX-99.1 2 spry-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray) $32.5 million in revenue, including $31.3 million in neffy U.S. net product revenue in third quarter of 2025 Continued U.S. product growth driven by direct-to-consumer (DTC) investments and real-world evidence, expected to accelerate with seamless prescribing experience Strong balance sheet of $288.2 million cash, cas…
Read attachment ↗